De Bodo has a big portfolio of high-profile clients including companies like Pfizer, Sharp, Seiko Epson and others. He has also represented pharmaceutical companies like GlaxoSmithKline, APP Pharmaceuticals and Eli Lilly in patent litigation.
In Bingham McCutchen, De Bodo will serve as co-chair of the Intellectual Property and Life Sciences practice groups. Other members of the group joining the firm with De Bodo include Siegmund Gutman, Andrew Devkar, Olga Berson and Bruce Kuyper. The group has significant industry connections in the U.S. and Japan.
Welcoming the group, Bingham Chairman Jay Zimmerman said the group’s “cutting-edge patent litigation practice perfectly complements our existing IP practice as well as our Japan practice, which includes more than 70 lawyers in Tokyo. It’s a strong and ideal fit.”
Speaking on the abilities of De Bodo, Geoff Howard, co-chair of Bingham’s Litigation Area observed, “Rich is one of the pre-eminent patent trial lawyers and litigators in the country, and he and his team will allow us to help clients protect their innovations, intellectual assets and technology in a global marketplace.”
On his side, explaining his decision to leave DLA Piper, De Bodo said, “We were extremely impressed with Bingham … It’s a well-run firm that is very strategic in its approach. We feel our biologics and electronics practice will develop and grow at Bingham, and our clients will be very well served. Our Japanese clients will benefit enormously from Bingham’s outstanding Japanese office and practice. We look forward to working with our new colleagues.”
